BC was the strongest bacterial treatment in down regulating HER-2 in LS174T cells (the same strength as trastuzumab and only second to cetuximab) but did not significantly change this tumor marker’s expression among IEC-18 cells (in contrast to the drugs). Here, ERBB2 is linked to breast cancer.